荷兰黑色素瘤治疗登记研究:荷兰转移性黑色素瘤诊疗的质量保障
荷兰于2013年7月建立全国性荷兰黑色素瘤治疗登记研究(DMTR),登记所有不可切除IIIC期或IV期黑色素瘤患者,收集肿瘤与患者特征、治疗模式、临床结局、生活质量、医疗利用等数据,用于临床审计、透明化诊疗、真实世界成本效果分析和研究平台。1年内所有黑色素瘤中心参与;质量指标显示BRAF抑制剂和伊匹木单抗安全引入,毒性率与III期试验一致。接受全身治疗患者的中位总生存第一登记年为10.1个月(95%CI 9.1-11.1),第二年为12.7个月(95%CI 11.6-13.7)。
要点
- DMTR为全国性多目的登记研究,覆盖所有不可切除IIIC期或IV期黑色素瘤患者。
- 质量指标显示BRAF抑制剂和伊匹木单抗毒性率与III期试验一致。
- 全身治疗患者中位总生存第一年10.1个月,第二年12.7个月。
核心结论
- DMTR是首个综合性多目的全国登记研究,与黑色素瘤诊疗相关各方合作体现整合性癌症管理视角。
- 未来DMTR将为界定从新药中获益最大的可能患者亚组等难题提供见解。
研究设计与样本
- 荷兰于2013年7月建立基于人群的荷兰黑色素瘤治疗登记研究(DMTR),登记所有荷兰不可切除IIIC期或IV期黑色素瘤患者。
- 登记内容包括肿瘤与患者特征、治疗模式、临床结局、生活质量、医疗利用、非正式照护和生产力损失。
主要发现
- 1年内所有黑色素瘤中心参与DMTR。
- 质量绩效指标显示BRAF抑制剂和伊匹木单抗在荷兰安全引入,毒性率与已开展的III期试验一致。
- 接受全身治疗患者的中位总生存第一登记年为10.1个月(95%CI 9.1-11.1),第二年为12.7个月(95%CI 11.6-13.7)。
关键数值与推荐
- 接受全身治疗患者的中位总生存第一登记年10.1个月(95%CI 9.1-11.1) vs 第二登记年12.7个月(95%CI 11.6-13.7)。
临床怎么用
- DMTR数据用于临床审计、提高黑色素瘤诊疗透明度、提供真实世界成本效果见解并创建研究平台。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recent years, the treatment of metastatic melanoma has changed dramatically due to the development of immune checkpoint and mitogen-activated protein (MAP) kinase inhibitors. A population-based registry, the Dutch Melanoma Treatment Registry (DMTR), was set up in July 2013 to assure the safety and quality of melanoma care in the Netherlands. This article describes the design and objectives of the DMTR and presents some results of the first 2 years of registration. METHODS: The DMTR documents detailed information on all Dutch patients with unresectable stage IIIc or IV melanoma. This includes tumour and patient characteristics, treatment patterns, clinical outcomes, quality of life, healthcare utilisation, informal care and productivity losses. These data are used for clinical auditing, increasing the transparency of melanoma care, providing insights into real-world cost-effectiveness and creating a platform for research. RESULTS: Within 1 year, all melanoma centres were participating in the DMTR. The quality performance indicators demonstrated that the BRAF inhibitors and ipilimumab have been safely introduced in the Netherlands with toxicity rates that were consistent with the phase III trials conducted. The median overall survival of patients treated with systemic therapy was 10.1 months (95% confidence interval [CI] 9.1-11.1) in the first registration year and 12.7 months (95% CI 11.6-13.7) in the second year. CONCLUSION: The DMTR is the first comprehensive multipurpose nationwide registry and its collaboration with all stakeholders involved in melanoma care reflects an integrative view of cancer management. In future, the DMTR will provide insights into challenging questions regarding the definition of possible subsets of patients who benefit most from the new drugs.
引用
- Jochems A, Schouwenburg MG, Leeneman B, et al. Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. Eur J Cancer. 2016. PMID: 28030784. doi:10.1016/j.ejca.2016.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。